Equillium, Inc. (EQ): auditor change — Equillium ends Biocon itolizumab deal, dismisses KPMG, two directors resign

Equillium, Inc.

Terminated collaboration with Biocon; all itolizumab licenses reverted. Technical service fee of $363k set-off against amounts owed.
Dismissed KPMG as auditor (effective Sep 30); engaged Crowe LLP pending finalization. KPMG reports had going-concern qualification.
Directors Stephen Connelly (Ph.D.) and Bala Manian (Ph.D.) resigned effective Oct 1; board reduced from 9 to 7.
Appointed Dr. Connelly as President (remains CSO); no comp change. Daniel Bradbury shifted from Executive Chairman to Chairman.

item 4.01 item 5.02 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Auditor Changes SEC 8-K Item 4.01/4.02 confidence 0.9

Equillium, Inc. engaged Crowe LLP as its auditor.

Action: engagement
Auditor: Crowe LLP

Exact text from the filing

On September 30, 2025, the Audit Committee approved the engagement of Crowe LLP (“Crowe”) as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2025, subject to the execution of an engagement letter and completion of Crowe’s standard client acceptance procedures.

View on SEC.gov

Auditor Changes SEC 8-K Item 4.01/4.02 confidence 0.9

Equillium, Inc. dismissed KPMG LLP as its auditor.

Action: dismissal
Auditor: KPMG LLP

Exact text from the filing

On September 30, 2025, the Audit Committee (the “Audit Committee”) of the Board of Directors (the “Board”) of Equillium, Inc. (the “Company”) approved dismissal of KPMG LLP (“KPMG”) as the Company’s independent registered public accounting firm, with such dismissal to become effective on September 30, 2025.

View on SEC.gov

6 auditor changes filed in the last 30 days. Browse all auditor changes →

Equillium, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-25-231860

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.